Calmark receives its first order from Triolab AB in Sweden

Calmark Sweden AB has today received the Company's first order for the Calmark Neo platform. The order covers both the reader and single-use tests for bilirubin, and was placed by Triolab AB, which is Calmark's exclusive distributor in Sweden. 

Today's announcement entails that one of the most important milestones for 2020, as laid out in Calmark's information memorandum in 2019, has now been achieved.

"I am extremely happy and proud that we have received the first order in company history," says Magdalena Tharaldsen, Calmark's Director International Business Development. "Triolab is now fully underway with their marketing activities related to our products, and we are very happy with their effort." 

"This is a historic day and a milestone that marks Calmark's transition from development company to selling company," says Anna Söderlund, CEO of Calmark. "I look forward to the global launch phase that we are now entering."

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 14 September 2020, 16:30 CEST.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.